Editorial
Will the ultra-low-dose intraoperative X-ray imager change thoracoscopic surgery?
Translational Lung Cancer Research
2022;
11
(4)
:506-508
.
(29 April 2022)
Original Article
Identification of heritable rare variants associated with early-stage lung adenocarcinoma risk
Translational Lung Cancer Research
2022;
11
(4)
:509-522
.
(29 April 2022)
Macrophages-based immune-related risk score model for relapse prediction in stage I–III non-small cell lung cancer assessed by multiplex immunofluorescence
Translational Lung Cancer Research
2022;
11
(4)
:523-542
.
(29 April 2022)
Picropodophyllin inhibits the growth of pemetrexed-resistant malignant pleural mesothelioma via microtubule inhibition and IGF-1R-, caspase-independent pathways
Translational Lung Cancer Research
2022;
11
(4)
:543-559
.
(29 April 2022)
Role of radiomics in predicting lung cancer spread through air spaces in a heterogeneous dataset
Translational Lung Cancer Research
2022;
11
(4)
:560-571
.
(29 April 2022)
Plasma extracellular vesicle long RNA profiling identifies a diagnostic signature for stage I lung adenocarcinoma
Translational Lung Cancer Research
2022;
11
(4)
:572-587
.
(29 April 2022)
Ultra-low-dose intraoperative X-ray imager for minimally invasive surgery: a pilot imaging study
Translational Lung Cancer Research
2022;
11
(4)
:588-599
.
(29 April 2022)
Resection and reconstruction via median sternotomy incision for tracheal tumors
Translational Lung Cancer Research
2022;
11
(4)
:600-606
.
(29 April 2022)
A nomogram for predicting hyperprogressive disease after immune checkpoint inhibitor treatment in lung cancer
Translational Lung Cancer Research
2022;
11
(4)
:607-616
.
(29 April 2022)
Clinicopathologic characteristics and diagnostic methods of RET rearrangement in Chinese non-small cell lung cancer patients
Translational Lung Cancer Research
2022;
11
(4)
:617-631
.
(29 April 2022)
Systematic analysis of ferroptosis-related long non-coding RNA predicting prognosis in patients with lung squamous cell carcinoma
Translational Lung Cancer Research
2022;
11
(4)
:632-646
.
(29 April 2022)
The efficacy and safety of albumin-bound paclitaxel plus carboplatin as neoadjuvant therapy for potentially resectable lung squamous cell carcinoma: a real-world retrospective cohort study
Translational Lung Cancer Research
2022;
11
(4)
:647-655
.
(29 April 2022)
The clinical outcome and risk factors analysis of immune checkpoint inhibitor-based treatment in lung adenocarcinoma patients with brain metastases
Translational Lung Cancer Research
2022;
11
(4)
:656-669
.
(29 April 2022)
Deep learning for predicting immunotherapeutic efficacy in advanced non-small cell lung cancer patients: a retrospective study combining progression-free survival risk and overall survival risk
Translational Lung Cancer Research
2022;
11
(4)
:670-685
.
(29 April 2022)
iMDT Corner
Osimertinib as induction therapy for oligometastatic non-small cell lung cancer with EGFR mutation: a case report
Translational Lung Cancer Research
2022;
11
(4)
:686-696
.
(29 April 2022)
Editorial Commentary
Durvalumab plus novel agents in non-small cell lung cancer—a new COAST on the horizon?
Translational Lung Cancer Research
2022;
11
(4)
:697-701
.
(29 April 2022)
Letter to the Editor
NICOLAS, DETERRED and KEYNOTE 799: focus on escalation of conventionally fractionated chemoradiotherapy by immune checkpoint inhibition in unresectable stage III non-small cell lung cancer
Translational Lung Cancer Research
2022;
11
(4)
:702-705
.
(29 April 2022)
